

A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer

Status: Recruiting

Eligibility Criteria

Sex: Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy

Exclusion Criteria:

- primary invasive ovarian or cervical cancer occurring with this cancer - other cancer occurring in the past 5 years - active or history of autoimmune disease or immune deficiency - history of cardiac, respiratory or neurological conditions (study staff will review)

Conditions & Interventions

Interventions:

Drug: Abemaciclib, Drug: Atezolizumab - 21 Day Cycle, Drug: Atezolizumab - 28 Day Cycle, Drug: Bevacizumab, Drug: Giredestrant, Drug: Inavolisib, Drug: Ipatasertib, Drug: Letrozole, Drug: Talazoparib, Drug: Tiragolumab, Drug: Trastuzumab emtansine

Conditions:

Cancer, Women's Health

Keywords:

Clinics and Surgery Center (CSC), EndoCA, Endometrial Cancer

More Information

Description: The purpose of this study is to learn the effects, good or bad, of several possible study treatments for EndoCA that are selected based on genetic markers that can be found in these tumors.

Study Contact: Britt Erickson - bkeric@umn.edu

Principal Investigator: Britt Erickson

Phase: Phase 1/Phase 2

IRB

Number: SITE00001240

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.